Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Companies

Korea Health Industry Development Institute

Korea Health Industry Development Institute
KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.

The company in detail

Profile

Professional institute leading the promotion of health industry and the technological development for building up advanced nation in the field of Bio-technology in the 21st century.

• Established the Korea Health Industry Development Institute (Feb. 6, 1999)

• Designated as an organization evaluation health industry venture companies (Small and Medium Business Administration)

• Designated as a R&D Management Institute (Health and Medical Technology Promotion Act, Act No. 6161)

• Designated as a "national health technology valuation and transfer institution" (Ministry of Health and Welfare)

• Designated as a Good Manufacturing Practices education institute (Korea Food & Drug Administration)

Major Activities of KHIDI

• Development of Policy and Strategy for Health Industry Promotion

• Promotion of Pharmaceutical and Cosmetic Industry

• Promotion of Food Industry

• Promotion of Medical Devices and Health Informatics

• Promotion of Healthcare Industry

• Quality Testing and Evaluation

• Research Planning and Evaluation Service

• Project for Commercialization

• Export Promotion and International Trade Cooperation

• Human Resources Development

Health Technology Transfer Center (HTTC-KHIDI)

• HTTC-KHIDI is a professional health technology transfer center established in Jan. 2001 as a platform for the circulation of health technology by providing various service on technology transfer, technology valuation through the domestics and overseas network. TC switches

• HTTC-KHIDI is a subsidiary of KHIDI, which is a government-supported institute under the Ministry of Health and Welfare established for the promotion of health industry and public health.

Major Activities of HTTC-KHIDI:

• Technology Transfer to other countries: Providing opportunities for overseas technology transfer, strategic partnering and investment for the excellent domestic health industries

• Support Program for the Patent Fee: Support for the patent process expense of the health technologies to promote their transfer and commercialization

• Company IR and Partnering: Provide an opportunity for biotechnology and pharmaceutical companies, research institutions, bio-clusters and investors from around the world to meet and network with potential business and technology partners, and to discuss business opportunities of mutual interests through one-on-one meetings.

Partnering strategy/interests

KHIDI will commercialise several technologies and products of KHIDI's client companies via collaboration with partners. KHIDI seeks out business partners and licenses at various stages of early drug development for client companies.

Out-licensing

Ob-X is composed of herbal extracts, and reduced body and adipose tissue weight and number and size of lipid vacuoles in the liver in animal studies; reduced body weight, waist circumference and visceral fat in human studies More
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
We have technology to produce chiral intermediates of high quality by biotransformation More
Our products (KH-207 and KD-30) related to treatment of osteoarthritis focus on increase of chondrogenesis through cartilage protection as well as beneficial effects (decrease of pain and stiffness and improvement of function). We propose an alterna More
asthma, atopic dermatitis, allergic rhinitis More
Gene-therapy product combining pCK naked DNA vector with genetically engineered Hepatocyte Growth Factor gene More
Production process of C3 synthons by biotransformation. More
Disclosed herein are a pharmaceutical formulation with high stability and dissolution, and a method for preparing the pharmaceutical formulation, More
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May More
Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
A pharmaceutical composition comprising HS024 as an active ingredient in an amount effective to protect neuronal cell and to treat or prevent human or mammal suffering from brain diseases such as brain stroke and degenerative brain diseases, together More
ω-conopeptide FVIA recently has developed an innovative pharmaceutical composition for preventing or treating diseases, disorders or conditions associated with N-type calcium channel activity More
Diabetic retinopathy is one of the most common microvascular complications of diabetes, affecting nearly 50% of patients with diabetes. Diabetic retinopathy can affect almost anyone with diabetes, while an additional 5.4 million have undiagnosed dia More
Lotuzol is a new herbal drug composing water extract powder of Nelumbinis Semen to treat depression without sexual dysfunction, a major adverse effect in commonly used anti-depressants. More
Cinnamic acid derivatives are good candidates to satisfy this unmet medical need More
Guided Bone Regeneration Membrane in Dental Surgery More
PWG has various business portfolios to supply SPF Micro-pig®s, CRO services for GLP studies using Micro-pig®s, development of specific disease models, and bioproducts such as artifical organs and cells. More
Direct gene amplification using AnyDirect solution gives reliable results from crude biospecimens without DNA isolation or any instrument. More
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
This technology is related to optimal conditions for culturing stem cells and feeder cells More
The cultured autologous squamous epithelium, which differentiates into mucociliary epithelium after in vivo grafting, are remarkably effective in airway luminal reconstruction. More
Two types of vaccines for preventing and treating allergic diseases including atopic dermatitis, allergic asthma, allergic rhinitis, allergic conjunctivitis, and urticaria. More

Press Releases

(5th Mar 2008) BIO KOREA 2008, South Korea's largest biotech show, is the third edition this year. More

Head office

Korea Health Industry Development Institute
57-1 Noryangjin-Dong, Dongjak-Gu
Seoul
156-800
South Korea

Tel:  +82 2 2194 7350
Fax: +82 2 824 1762
www | email

Contact details

Young-Kyun Jung
Researcher
Technology Business Center
Request more information
Young-Kyun Jung
Researcher
Technology Business Center
Request more information
Bo-Young Um
Senior Researcher
Health Technology Transfer Center
Request more information
Yong U Kim
Researcher
Technology Business Center
Request more information
Hwang Yong-Chul
Researcher
Technology Business Center
Request more information
Byung-ll Park
Ph.D
Technology Business Center
Request more information
Ju-Don Lee
Head Researcher
Technology Business Center
Request more information

Company figures

Formed: 1999
Number of employees: 154

Related categories

Partnering consultation free of charge
Maximizing Pharmaceutical Patent Lifecycles
Yissum Technology Transfer Hebrew University
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us